Summary
GeneDx: Why I Think The Selloff Went Too Far
GeneDx shares have collapsed 65% since November, but I assign a buy rating due to strong volume growth and undervaluation versus peers. Despite a 34% YoY volume increase, revenue growth lagged at 27% due to lower reimbursement rates from a shift to genome testing. WGS owns one of the largest rare disease genomic databases, creating a durable competitive advantage and potential for AI-driven value creation.
GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Lags Revenue Estimates
GeneDx Holdings Corp. (WGS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.28 per share a year ago.
Will Robust Exome and Genome Revenues Lift GeneDx's Q1 Earnings?
GeneDx heads into Q1 earnings results with strong exome and genome momentum, supported by expanding adoption and a growing rare-disease data advantage.
GeneDx Holdings Corp. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 32 | $2,603.49 | $2,031.36 | -$572.13 | -21.98% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1 | $130.06 | $63.63 | -$66.43 | -51.08% |
 Farallon Capital Farallon Capital Management LLC | 5,000 | $650,300 | $315,850 | -$334,450 | -51.43% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 9,220 | $915,952.7 | $582,427.4 | -$333,525.3 | -36.41% |
| BG Bart Gancher Intech Investment Management LLC | 4,939 | $455,919.09 | $314,614.3 | -$141,304.79 | -30.99% |
GeneDx Holdings Corp. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Mark Massaro BTIG | 14.7 | $595.29 | $972.16 | $376.87 | 63.31% |
 Brandon Couillard Wells Fargo | 527.4 | $33,363.23 | $31,818.27 | -$1,544.96 | -4.63% |
GeneDx Holdings Corp. (WGS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has GeneDx Holdings Corp. ever had a stock split?
GeneDx Holdings Corp. Profile
| Biotechnology Industry | Healthcare Sector | Katherine A. Stueland CEO | NASDAQ (NGS) Exchange | 81663L200 CUSIP |
| US Country | 1,300 Employees | - Last Dividend | 4 May 2023 Last Split | 4 Nov 2020 IPO Date |
Overview
GeneDx Holdings Corp. is a pioneering entity in the field of genomics, delivering a wide array of diagnostic and information services through its subsidiaries since its inception in 2017. Headquartered in Stamford, Connecticut, the company strides ahead with a robust commitment to enhancing healthcare through genomics. It stands out in the medical community for integrating advanced digital tools and artificial intelligence within its operations, which significantly boosts its capability to offer comprehensive health insights. The focus on pediatrics, rare diseases for both children and adults, as well as hereditary cancer screening, positions GeneDx Holdings Corp. as a key player in the advancement of personalized and precision medicine.
Products and Services
- Centrellis Health Intelligence Platform - An AI-driven platform that revolutionizes the way health data is used. Centrellis integrates digital tools and artificial intelligence, enabling researchers and scientists to efficiently ingest, process, and synthesize clinical and genomic data. This integration facilitates the delivery of comprehensive health insights, aiding in the advancement of personalized medicine and enhancing patient care outcomes.
- Genetic Diagnostic Tests - GeneDx Holdings Corp. offers an extensive range of genetic diagnostic tests aimed at identifying genetic disorders at an early stage. These tests are pivotal in detecting a variety of conditions, enabling healthcare providers to devise appropriate treatment and management plans tailored to the individual needs of patients.
- Screening Solutions - The company provides state-of-the-art screening solutions that play a crucial role in preemptive health care. These solutions are designed to detect potential health issues before they become serious, thereby enabling timely intervention and reducing the overall healthcare burden.
- Information Services - With a strong emphasis on pediatrics, rare diseases, and hereditary cancer screening, GeneDx Holdings Corp. extends comprehensive information services. These services are rooted in the latest research and innovations in genomics, offering invaluable support to both healthcare providers and patients in navigating complex health conditions and making informed decisions.
